Lp(a) and Cardiovascular Risk: Advancing Awareness, Testing, and Management in Clinical Practice : Episode 13

Opinion

Video

April 28, 2025

The Benefits of Lp(a) Testing in the Absence of Lp(a)-Lowering Therapies

Author(s):

Nihar Desai, MD, MPH,Nathan Wong, PhD

Experts discuss how lipoprotein(a) (Lp[a]) testing, even without targeted Lp(a)-lowering therapies, can enhance overall cardiovascular risk assessment and potentially influence the management of other risk factors.

EP: 1.Lp(a) in ASCVD and Guideline Recommendations

EP: 2.Introduction and Burden of Atherosclerotic Disease and Aortic Stenosis

EP: 3.The Role of Prevention in the Management of Atherosclerotic Disease and Aortic Stenosis

EP: 4.Studying the Association Between Elevated Lp(a) Levels and Risk of Atherosclerotic Disease

EP: 5.Lp(a) Levels: A Continuous Relationship With ASCVD Levels and Consistent Throughout a Lifetime

EP: 6.How the Genetic Nature of Lp(a) Levels Influences Screening

EP: 7.A Case Study of Elevated Lp(a) Levels and Increased ASCVD Risk

EP: 8.The Role of Management Guidelines in Formulary Decision-Making and Recent Lp(a) Recommendations

EP: 9.Evidence Supporting 2024 Guidance for Lp(a) Testing

EP: 10.Factoring Cost, Recommendations, and Evidence Into Formulary Decisions about Lp(a) Testing

EP: 11.Assessing the Quality of Recommendations and Making Clinical Decisions About Lp(a) Testing

EP: 12.FDA-Approved and Pipeline Treatments for Elevated Lp(a) Levels

EP: 13.The Benefits of Lp(a) Testing in the Absence of Lp(a)-Lowering Therapies

EP: 14.Results of Lp(a) Testing to Modify Risk Assessment and Optimize Treatment

EP: 15.Lp(a) Testing: Prevalence and Strategies to Improve Uptake

EP: 16.Implementing Lp(a) Testing in Health Systems: Lessons From Real-World Experience

EP: 17.Implementing Lp(a) Testing: Learning From LDL Testing and Considering Value-Based Care Models

EP: 18.Present and Looking to the Future: Lp(a) Testing and Atherosclerotic Disease Management

Video content above is prompted by the following:

Previously, I mentioned the benefits of Lp(a) testing, even in the absence of targeted Lp(a)-lowering therapies. Let’s explore that further. How might Lp(a) testing improve overall cardiovascular risk assessment?
How, if at all, might Lp(a) measurement influence the management of other risk factors?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos

5 experts are featured in this series

2 experts in this video

5 experts are featured in this series

2 experts in this video

Related Content

Eliquis packaging | Image credit: Semi – stock.adobe.com

July 17th 2025

Direct-to-Patient Apixaban Program Aims to Expand Access, Lower Out-of-Pocket Costs

Hayden E. Klein

Apixaban would still cost patients 9 times more through the Eliquis 360 Support program than with commercial insurance.

Managed Care Cast

May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi

In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.

Cardiologist listening to patient's heart | Image credit: Space_Cat – stock.adobe.com

June 19th 2025

40% of Patients With Heart Failure Don’t See Cardiologist Annually, Increasing Risk of Death

Hayden E. Klein

Patients who see a cardiologist at least once a year are about 24% less likely to die in the following year.

May 10th 2022

For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management

On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.

CBD oils and hemp leaves | Image credit: Irina_Evva – stock.adobe.com

May 23rd 2025

CBD-Based Drug Shows No Heart Safety Risks in Patients With CVD or Risk Factors

Hayden E. Klein

A pharmaceutical-grade cannabidiol (CBD) product was shown to be safe in high-risk patients hospitalized with COVID-19, with no increased rate of cardiac side effects compared with placebo.

AJMC

May 16th 2025

Predicting Mortality Risk Using the PREVENT Equation Across Diverse Racial Groups

Ofer Kobo, MD Martin K. Rutter, MD Shivani Misra, PhD Erin D. Michos, MD, MHS Phyo K. Myint, MD Ariel Roguin, MD, PhD Louise Y. Sun, MD Mamas A. Mamas, MD

This study validates the Predicting Risk of CVD Events (PREVENT) score across diverse racial and ethnic populations, highlighting its effectiveness in predicting cardiovascular risk and mortality, regardless of race or ethnicity.

Related Content

Eliquis packaging | Image credit: Semi – stock.adobe.com

July 17th 2025

Direct-to-Patient Apixaban Program Aims to Expand Access, Lower Out-of-Pocket Costs

Hayden E. Klein

Apixaban would still cost patients 9 times more through the Eliquis 360 Support program than with commercial insurance.

Managed Care Cast

May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi

In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.

Cardiologist listening to patient's heart | Image credit: Space_Cat – stock.adobe.com

June 19th 2025

40% of Patients With Heart Failure Don’t See Cardiologist Annually, Increasing Risk of Death

Hayden E. Klein

Patients who see a cardiologist at least once a year are about 24% less likely to die in the following year.

May 10th 2022

For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management

On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.

CBD oils and hemp leaves | Image credit: Irina_Evva – stock.adobe.com

May 23rd 2025

CBD-Based Drug Shows No Heart Safety Risks in Patients With CVD or Risk Factors

Hayden E. Klein

A pharmaceutical-grade cannabidiol (CBD) product was shown to be safe in high-risk patients hospitalized with COVID-19, with no increased rate of cardiac side effects compared with placebo.

AJMC

May 16th 2025

Predicting Mortality Risk Using the PREVENT Equation Across Diverse Racial Groups

Ofer Kobo, MD Martin K. Rutter, MD Shivani Misra, PhD Erin D. Michos, MD, MHS Phyo K. Myint, MD Ariel Roguin, MD, PhD Louise Y. Sun, MD Mamas A. Mamas, MD

This study validates the Predicting Risk of CVD Events (PREVENT) score across diverse racial and ethnic populations, highlighting its effectiveness in predicting cardiovascular risk and mortality, regardless of race or ethnicity.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions